Moderna (NASDAQ:MRNA) Stock Price Expected to Rise, Berenberg Bank Analyst Says

Moderna (NASDAQ:MRNA - Get Free Report) had its target price upped by research analysts at Berenberg Bank from $33.00 to $42.00 in a note issued to investors on Thursday. The firm presently has a "hold" rating on the stock. Berenberg Bank's price objective suggests a potential upside of 24.46% from the stock's current price.

A number of other brokerages also recently issued reports on MRNA. HSBC raised Moderna from a "hold" rating to a "buy" rating and set a $58.00 price target on the stock in a research report on Monday, November 18th. JPMorgan Chase & Co. dropped their target price on shares of Moderna from $59.00 to $45.00 and set an "underweight" rating on the stock in a research report on Tuesday, November 26th. Barclays decreased their price target on shares of Moderna from $125.00 to $111.00 and set an "overweight" rating for the company in a report on Friday, November 8th. Sanford C. Bernstein began coverage on shares of Moderna in a report on Thursday, October 17th. They set a "market perform" rating and a $55.00 price objective on the stock. Finally, Royal Bank of Canada reaffirmed a "sector perform" rating and set a $75.00 target price on shares of Moderna in a report on Thursday, September 19th. Four investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $75.58.

Moderna Trading Down 2.9 %

Shares of Moderna stock traded down $1.02 on Thursday, hitting $33.75. 6,240,972 shares of the company traded hands, compared to its average volume of 12,270,938. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. The stock's 50 day moving average price is $41.44 and its 200-day moving average price is $67.56. The company has a market cap of $12.99 billion, a PE ratio of -5.80 and a beta of 1.60. Moderna has a 52 week low of $31.94 and a 52 week high of $170.47.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The company reported $0.03 EPS for the quarter, topping analysts' consensus estimates of ($1.89) by $1.92. The company had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. Moderna's revenue for the quarter was up 3.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.39) earnings per share. Equities research analysts predict that Moderna will post -9.3 EPS for the current year.

Insider Activity at Moderna

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the company's stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the transaction, the insider now directly owns 19,717 shares of the company's stock, valued at approximately $843,690.43. This represents a 6.71 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last 90 days, insiders have sold 2,664 shares of company stock worth $115,210. 15.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Moderna

Institutional investors and hedge funds have recently made changes to their positions in the business. Axiom Advisory LLC increased its holdings in shares of Moderna by 1.6% in the 3rd quarter. Axiom Advisory LLC now owns 12,672 shares of the company's stock valued at $847,000 after purchasing an additional 198 shares in the last quarter. Arkadios Wealth Advisors grew its position in shares of Moderna by 2.2% in the third quarter. Arkadios Wealth Advisors now owns 11,429 shares of the company's stock valued at $764,000 after purchasing an additional 243 shares during the last quarter. Knuff & Co LLC increased its stake in shares of Moderna by 5.4% during the 3rd quarter. Knuff & Co LLC now owns 4,732 shares of the company's stock worth $316,000 after purchasing an additional 244 shares in the last quarter. Stephens Inc. AR raised its position in shares of Moderna by 7.9% during the 3rd quarter. Stephens Inc. AR now owns 3,334 shares of the company's stock worth $223,000 after purchasing an additional 245 shares during the last quarter. Finally, Mather Group LLC. lifted its stake in Moderna by 25.7% in the 3rd quarter. Mather Group LLC. now owns 1,281 shares of the company's stock valued at $86,000 after buying an additional 262 shares in the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.